Cara Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shelton CT United States (2004)

Organization Overview

First Clinical Trial
2009
NCT00877799
First Marketed Drug
2021
difelikefalin
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

CARA THERAP | Cara Therapeutics | Cara Therapeutics, Inc.